Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9

  • Laura Ulitzky,

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

  • Manuel M. Lafer,

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

  • Mark A. KuKuruga,

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

  • Erica Silberstein,

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

  • Nicoleta Cehan,

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

  • Deborah R. Taylor

    Deborah.Taylor@fda.hhs.gov

    Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993–0002, United States of America

A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9

  • Laura Ulitzky, 
  • Manuel M. Lafer, 
  • Mark A. KuKuruga, 
  • Erica Silberstein, 
  • Nicoleta Cehan, 
  • Deborah R. Taylor
PLOS
x

Viewed info

Cited info

Saved info

Discussed info

Questions or concerns about usage data? Please let us know.